In 2020, SCP started thematic research of the outsourced pharma services market, identifying five sub-sectors for deeper deal-focused research. The safety services and pharmacovigilance (“PV”) market was identified as a key target.

Using its research, our team was able to identify the Clario subsidiary, Drug Safety and Pharmacovigilance Services Solutions (“DSS”) early as a target investment.